Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Research & Development (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Research & Development for 10 consecutive years, with $36940.0 as the latest value for Q4 2022.

  • Quarterly Research & Development rose 42.09% to $36940.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $176431.0 through Dec 2022, down 10.78% year-over-year, with the annual reading at $165758.0 for FY2025, 0.84% up from the prior year.
  • Research & Development hit $36940.0 in Q4 2022 for Kraig Biocraft Laboratories, down from $62118.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $87768.0 in Q1 2021 to a low of $20127.0 in Q1 2018.
  • Historically, Research & Development has averaged $40631.5 across 4 years, with a median of $39254.0 in 2021.
  • Biggest five-year swings in Research & Development: crashed 82.37% in 2018 and later soared 117.53% in 2019.
  • Year by year, Research & Development stood at $56827.0 in 2018, then decreased by 22.59% to $43987.0 in 2019, then crashed by 40.9% to $25997.0 in 2021, then surged by 42.09% to $36940.0 in 2022.
  • Business Quant data shows Research & Development for KBLB at $36940.0 in Q4 2022, $62118.0 in Q3 2022, and $49869.0 in Q2 2022.